Bio Path Holdings Inc (BPTH)

[SJSTOCKSHARK]

Surprise, surprise, surprise!

This presentation was PN's best.

He explained well the cell reproduction interruption of the Grb-2 protein by our drug (slide 9) and how it stops cancer.

He gave out some good information on why the new patents were needed and the process taken by the company to secure the delivery system (slide 8). He is actively pursuing partnerships for our delivery system now that we have 20 year patent protection. He believes 5 or 6 new patents can taken out under this present patent.

We now have 50 evaluable patents who completed AML testing. Subtract the 41 at end of the safety cohorts (slide 11) and that is 9 additional patients who have finished combination phase II testing. PN said while it is early, so far the patient response has been favorable compared to the established thresholds. Over 50 patients (with no toxicity) have been enrolled and we are on schedule to meet to meet the end of the year target for the 19 patients needed to covert the study and apply for fast track approval. Enrollment in the combination trial for additional patients is happening very quickly now. IMO this is because the testing facilities see that the drug is working.

The CML combination trial was scheduled for the week of Harvey so it was delayed. PN believes the combination safety cohort (6 patients) will start "in days" and also be concluded by years end. CML is huge for us as 33% of patients are resistant to Gleevec, the standard treatment (slide 15). Blast crisis and accelerated CML patients have less than 30% response to frontline treatment and a 9 month survival rate. There is a HUGE need here. (slide 16)

Is this the start of the rebound?

To me this is a positive change the company's disclosures. Let us hope it continues.